| Product No | EMEA/H/C/003840 |
|---|---|
| Brand Name | Nivolumab BMS |
| Nonproprietary Name | nivolumab |
| API | nivolumab |
| ATC Code | L01XC17 |
| Indications | Nivolumab BMS is indicated for the treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. |
| Orphan Drug | no |
| Generics | no |
| Marketing Authorization Holder | Bristol-Myers Squibb Pharma EEIG |
| Status | Withdrawn |
| Authorization Date | 2015-07-20 |
| Version | 0 |
| Condition Approval | no |
| Exceptions | no |
| Biosimilar | no |
| Details | 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息) |
Extended Information